Mydriacyl®
Tropicamide 1% · ophthalmic solution
Mydriatics/Cycloplegics
Approved uses
Cycloplegic refraction
1 or 2 drops of 1% in the eye(s), repeated in 5 minutes.
Cycloplegic shift averages 0.11 D less than cyclopentolate 1%, judged clinically insignificant.
Mydriasis for fundus examination
1 or 2 drops of 0.5% instilled 15 or 20 minutes before examination; heavily pigmented irides may require the higher strength or more doses.
Mydriasis begins in 15 to 30 minutes and reverses in 4 to 8 hours, up to 24 hours in some patients.
OFF-LABELNot in the FDA label for this product
Accommodative spasm (pseudomyopia)
1% BID, tapered against symptomatic response over about 2 months, alongside a single vision plus lens.
Case report · n=2
Evidence is a case report of 2 patients in Nepal with sudden fluctuating myopic refraction that shifted hyperopic under cycloplegia; both were managed with 1% twice daily plus a single vision plus lens and avoidance of triggering near work, with the dose tapered against symptomatic response and no recurrence reported over the follow-up. Case report level only: no control group, no comparison with cyclopentolate or atropine, and no dose-finding data.
Contraindications
Hypersensitivity to any component of this preparation.
Ophthalmic solution, 1% (3 mL, 15 mL) in plastic DROP-TAINER dispensers
Anticholinergic that blocks the response of the iris sphincter and the ciliary muscle to cholinergic stimulation, dilating the pupil; the 1% strength also paralyzes accommodation, while the weaker strength may be useful in producing mydriasis with only slight cycloplegia. Acts in 15 to 30 minutes with roughly 3 to 8 hours of activity, and complete recovery from mydriasis in some individuals may require 24 hours.
Warnings & Precautions
- CNS disturbances: This preparation may cause CNS disturbances which may be dangerous in pediatric patients; the possibility of psychotic reactions and behavioral disturbances due to hypersensitivity to anticholinergic drugs should be considered.
- Intraocular pressure elevation: Mydriatics may produce a transient rise.
- Excessive systemic absorption: The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to reduce excessive systemic absorption.
- Contact lens removal: Remove contact lenses before using.
- Interference with antihypertensive action: Tropicamide may interfere with the antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
- Not for injection: For topical ophthalmic use only.
Common Side Effects
Transient stinging, blurred vision, photophobia and superficial punctate keratitis have been reported with the use of tropicamide, and increased intraocular pressure has been reported following the use of mydriatics. Dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have also been reported with the use of tropicamide. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported with the use of anticholinergic drugs.
Pregnancy: No animal reproduction studies have been conducted and fetal harm is unknown; give only if clearly needed.
Lactation: Excretion in human milk is unknown; exercise caution in a nursing woman.
Tropicamide may rarely cause CNS disturbances which may be dangerous in pediatric patients. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported with the use of anticholinergic drugs.